A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

NCT06966154 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Natural Killer/T-cell Lymphoma
Relapsed or Refractory Lymphoma Including ENKL

Interventions

DRUG: tislezumab
DRUG: golidocitinib
DRUG: Selinexor

Sponsor

Fudan University